These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14611841)

  • 41. Design and synthesis of an orally active matrix metalloproteinase inhibitor.
    Yamamoto S; Nakatani S; Ikura M; Sugiura T; Nishita Y; Itadani S; Ogawa K; Ohno H; Takahashi K; Nakai H; Toda M
    Bioorg Med Chem; 2006 Sep; 14(18):6383-403. PubMed ID: 16765051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the inhibition of other metalloproteinases by matrix metalloproteinase inhibitors.
    Marcotte PA; Elmore IN; Guan Z; Magoc TJ; Albert DH; Morgand DW; Curtin ML; Garland RB; Guo Y; Heyman HR; Holms JH; Sheppard GS; Steinman DH; Wada CK; Davidsen SK
    J Enzyme Inhib; 1999; 14(6):425-35. PubMed ID: 10536876
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.
    Robinson RP; Laird ER; Blake JF; Bordner J; Donahue KM; Lopresti-Morrow LL; Mitchell PG; Reese MR; Reeves LM; Stam EJ; Yocum SA
    J Med Chem; 2000 Jun; 43(12):2293-6. PubMed ID: 10882354
    [No Abstract]   [Full Text] [Related]  

  • 44. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protease inhibitors. Part 12. Synthesis of potent matrix metalloproteinase and bacterial collagenase inhibitors incorporating sulfonylated N-4-nitrobenzyl-beta-alanine hydroxamate moieties.
    Scozzafava A; Ilies MA; Manole G; Supuran CT
    Eur J Pharm Sci; 2000 Jul; 11(1):69-79. PubMed ID: 10913755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
    Hanessian S; Moitessier N; Gauchet C; Viau M
    J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
    Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
    Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.
    Becker DP; Barta TE; Bedell L; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Mischke B; Munie GE; Swearingen C; Villamil CI
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2719-22. PubMed ID: 11591509
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxal hydroxamic acid derivatives with inhibitory activity against matrix metalloproteinases.
    Krumme D; Tschesche H
    Bioorg Med Chem Lett; 2002 Mar; 12(6):933-6. PubMed ID: 11958997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
    Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.
    Becker DP; DeCrescenzo G; Freskos J; Getman DP; Hockerman SL; Li M; Mehta P; Munie GE; Swearingen C
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2723-5. PubMed ID: 11591510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Protease inhibitors: synthesis of bacterial collagenase and matrix metalloproteinase inhibitors incorporating succinyl hydroxamate and iminodiacetic acid hydroxamate moieties.
    Santos MA; Marques S; Gil M; Tegoni M; Scozzafava A; Supuran CT
    J Enzyme Inhib Med Chem; 2003 Jun; 18(3):233-42. PubMed ID: 14506914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.
    Martin FM; Beckett RP; Bellamy CL; Courtney PF; Davies SJ; Drummond AH; Dodd R; Pratt LM; Patel SR; Ricketts ML; Todd RS; Tuffnell AR; Ward JW; Whittaker M
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2887-92. PubMed ID: 10522712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (radio)synthesis, in vitro and first in vivo evaluation.
    Hugenberg V; Riemann B; Hermann S; Schober O; Schäfers M; Szardenings K; Lebedev A; Gangadharmath U; Kolb H; Walsh J; Zhang W; Kopka K; Wagner S
    J Med Chem; 2013 Sep; 56(17):6858-70. PubMed ID: 23899323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel inhibitors of procollagen C-proteinase. Part 2: glutamic acid hydroxamates.
    Robinson LA; Wilson DM; Delaet NG; Bradley EK; Dankwardt SM; Campbell JA; Martin RL; Van Wart HE; Walker KA; Sullivan RW
    Bioorg Med Chem Lett; 2003 Jul; 13(14):2381-4. PubMed ID: 12824039
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Davis JM; Grosu GT; Baker J; Ellingboe J; Zask A; Levin JI; Sandanayaka VP; Du M; Skotnicki JS; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R; Tillett J; Zhao W; McDevitt J; Xu ZB
    J Med Chem; 2003 Jun; 46(12):2376-96. PubMed ID: 12773042
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
    Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
    Sheppard GS; Florjancic AS; Giesler JR; Xu L; Guo Y; Davidsen SK; Marcotte PA; Elmore I; Albert DH; Magoc TJ; Bouska JJ; Goodfellow CL; Morgan DW; Summers JB
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3251-6. PubMed ID: 9873712
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.
    Natchus MG; Bookland RG; De B; Almstead NG; Pikul S; Janusz MJ; Heitmeyer SA; Hookfin EB; Hsieh LC; Dowty ME; Dietsch CR; Patel VS; Garver SM; Gu F; Pokross ME; Mieling GE; Baker TR; Foltz DJ; Peng SX; Bornes DM; Strojnowski MJ; Taiwo YO
    J Med Chem; 2000 Dec; 43(26):4948-63. PubMed ID: 11150165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.